491 related articles for article (PubMed ID: 25997815)
1. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
Oh SY; Kwon HC; Jeong SH; Joo YT; Lee YJ; Cho Sh; Kang MH; Go SI; Lee GW; Kim Hg; Kang JH
Invest New Drugs; 2012 Feb; 30(1):350-6. PubMed ID: 20706861
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
[TBL] [Abstract][Full Text] [Related]
5. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
Sato Y; Sagawa T; Ohnuma H; Hirakawa M; Takahashi Y; Hamaguchi K; Fujikawa K; Nobuoka T; Okamoto K; Miyamoto H; Muguruma N; Takemasa I; Takayama T
Cancer Chemother Pharmacol; 2019 Jan; 83(1):161-167. PubMed ID: 30406285
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
8. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11.
Kim HS; Ryu MH; Zang DY; Park SR; Han B; Kang WK; Rha SY; Jung M; Kim JS; Kang BW; Lee KH; Rho SY; Kim JH; Kim KC; Cho JW; Choi DR; Lim H; Kang HS; Soh JS; Kim MJ; Seo J; Kang YK
Gastric Cancer; 2018 Sep; 21(5):802-810. PubMed ID: 29372461
[TBL] [Abstract][Full Text] [Related]
10. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
11. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E
Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
Anter AH; Abdel-Latif RM
Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
[TBL] [Abstract][Full Text] [Related]
14. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L
Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Di Lauro L; Vici P; Belli F; Tomao S; Fattoruso SI; Arena MG; Pizzuti L; Giannarelli D; Paoletti G; Barba M; Sergi D; Maugeri-Saccà M
Gastric Cancer; 2014 Oct; 17(4):718-24. PubMed ID: 24318671
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J
Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
Zang DY; Yang DH; Kim MJ; Jang KM; Hwang SW; Yoo KS; Han T; Kim HY; Kim HJ; Kwon JH; Song HH; Park S; Jung JY; Kim HS; Kim JH
Cancer Chemother Pharmacol; 2009 Oct; 64(5):877-83. PubMed ID: 19190908
[TBL] [Abstract][Full Text] [Related]
19. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Goel G; Jauhri M; Negi A; Aggarwal S
Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]